DE
COMPANY
CALCISCON was founded in 2013 as a result of a breakthrough research in renal medicine by Dr. Andreas Pasch.
He investigated why the blood vessels of kidney patients calcify rapidly. This work led to the development of the T50, the first functional test for the assessment of Calcification Propensity. T50 identifies patients with high cardiovascular risk, and opens the possibility to slow down disease progression.

Calciscon offers its CE-marked T50 blood test to patients through accredited medical laboratories.

The basic underlying principle of T50 reflects a generalized phenomenon in the entire body, and is thus potentially applicable to multiple medical conditions. Measurement in blood is linked to cardiovascular risk. Measurement in urine may be linked to kidney stone formation. Measurement in amniotic fluid correlates with early rupture of the membranes in pregnancy. T50 may also be a driver of accelerated aging and disease progression of dementia.

Calciscon offers a measurement service for testing Calcification Propensity in blood, urine or other sample types, through its laboratories located in Nidau (Switzerland).
BOARD
PD DR. ANDREAS PASCH
Chairman of the Board
Founder and CMO
KARSTEN UHLMANN
Board Member
DR. PIERRE COMTE
Innosuisse Coach
DR. VINCENT LINDER
Board Member and CEO
PETER STEINMANN
Board Member
DR. SEPPO MAKINEN
Advisor
QUALITY MANAGEMENT
Calciscon maintains a quality management system in accordance with standard EN ISO 13485:2016.

This certification demonstrates that Calciscon meets the requirements for the development and commercialization of in vitro diagnostic products. 

Calciscon's products are CE certified according to the IVDD 98/79/EC directive. 

Download Certificate.
Would you like to know more about
Calciscon or our products?
Then please contact us. We look forward to hearing from you.


CALCISCON AG
Aarbergstrasse 5
2560 Nidau | Switzerland
Phone: 0041 32 530 88 60
Email: info@calciscon.com
CONTACT
© 2020 by CALCISCON | Privacy Policy